Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Selective Therapeutic Targeting of CD133+ Brain Tumour Initiating Cells in Glioblastoma
FY 2013-14
Summary
Glioblastoma (GBM) is a highly aggressive and infiltrative tumour, with patients suffering relapse within 9 months of diagnosis and eventual death. Within these tumours a small population of abnormal cells were identified that drove the formation of the tumour. These so-called brain tumour-initiating cells (BTIC) have been implicated in tumour resistance to chemotherapy and radiation therapy. Higher fractions of BTICs escaping therapy may explain why some patient tumours that initially responded to therapy subsequently show aggressive re-growth. Using gene signatures associated with these BTICs, we identified six FDA approved compounds that might selectively target them by inhibiting their self-renewal and proliferation capacity. This proposal aims to validate these compounds by applying our uniquely efficient and successful cell sorting techniques to separate bulk GBM tumour cells into BTIC and non-BTIC fractions. We will characterize the therapeutic activity of these compounds using both in vitro stem cell assays as well as in vivo human-mouse Xenograft models. The selective targeting of BTIC population that drives tumour formation and recurrence will lead to tumour regression and patient survival.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
311974
Name
Qazi Maleeha A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Selective Therapeutic Targeting of CD133+ Brain Tumour Initiating Cells in Glioblastoma
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brain Tumour; Brain Tumour Initiating Cells; Cd133+; Drug Discovery; Glioblastoma Multiforme; Therapeutic Drug Targeting
Abstract
Glioblastoma (GBM) is a highly aggressive and infiltrative tumour, with patients suffering relapse within 9 months of diagnosis and eventual death. Within these tumours a small population of abnormal cells were identified that drove the formation of the tumour. These so-called brain tumour-initiating cells (BTIC) have been implicated in tumour resistance to chemotherapy and radiation therapy. Higher fractions of BTICs escaping therapy may explain why some patient tumours that initially responded to therapy subsequently show aggressive re-growth. Using gene signatures associated with these BTICs, we identified six FDA approved compounds that might selectively target them by inhibiting their self-renewal and proliferation capacity. This proposal aims to validate these compounds by applying our uniquely efficient and successful cell sorting techniques to separate bulk GBM tumour cells into BTIC and non-BTIC fractions. We will characterize the therapeutic activity of these compounds using both in vitro stem cell assays as well as in vivo human-mouse Xenograft models. The selective targeting of BTIC population that drives tumour formation and recurrence will lead to tumour regression and patient survival.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Qazi, Maleeha A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~